Annual Secretarial Compliance Report for the Financial Year ended on 31.03.2026
Awaiting price reaction for this filing.
Citurgia Biochemicals Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26 as required under SEBI Regulation 24A. The report, issued by Practicing Company Secretaries Sumit Bajaj & Associates, reveals several compliance deviations. Trading in the company's equity shares was suspended during the year but was reinstated on February 9, 2026. The company failed to submit the Annual Secretarial Compliance Report for FY 2024-25 within the prescribed timeline and also delayed submission of its Annual Report under Regulation 34 and Financial Results under Regulation 33, citing operational constraints due to the trading suspension. The company has since appointed a Chief Financial Officer on May 28, 2026. Despite these delays, the company has confirmed compliance with applicable Secretarial Standards, SEBI regulations on insider trading, and maintenance of proper documents and policies.
The filing highlights governance concerns with delayed regulatory submissions and a trading suspension period. While trading resumed in February 2026 and the company states it is taking steps to strengthen compliance, investors should monitor if future filings are submitted on time to avoid further penalties or trading halts.